Novel Mutations in the Glucocerebrosidase Gene of Brazilian Patients with Gaucher Disease by Marina Siebert et al.
RESEARCH REPORT
Novel Mutations in the Glucocerebrosidase Gene
of Brazilian Patients with Gaucher Disease
Marina Siebert • Hugo Bock •
Kristiane Michelin-Tirelli • Janice C. Coelho •
Roberto Giugliani • Maria Luiza Saraiva-Pereira
Received: 19 February 2011 /Revised: 30 July 2012 /Accepted: 17 August 2012 /Published online: 9 October 2012
# SSIEM and Springer-Verlag Berlin Heidelberg 2012
Abstract Gaucher disease (GD) is an autosomal recessive
disorder resulting from glucocerebrosidase (GC) deficiency
due to mutations in the gene (GBA) coding for this enzyme.
We have developed a strategy for analyzing the entire GBA
coding region and applied this strategy to 48 unrelated
Brazilian patients with GD. We used long-range PCR,
genotyping based on the Taqman® assay, nested PCR, and
direct DNA sequencing to define changes in the gene. We
report here seven novel mutations that are likely to be
harmful: S125N (c.491G>A), F213L (c.756T>G), P245T
(c.850C>A), W378C (c.1251G>C), D399H (c.1312G>C),
982-983insTGC (c.980_982dupTGC), and IVS10þ1G>T
(c.1505þ1G>T). The last alteration was found as a
complex allele together with a L461P mutation. We also
identified 24 different mutations previously reported by
others. G377S was the third most frequent mutation among
the patients included in this study, after N370S and L444P.
Therefore, this mutation needs be included in preliminary
screens of Brazilian GD patients. The identification of
mutant GBA alleles is crucial for increasing knowledge
of the GBA mutation spectrum and for better understanding
of the molecular basis of GD.
Introduction
Gaucher disease (GD) is the most common lysosomal
storage disorder and results from an inborn deficiency of
the enzyme glucocerebrosidase (GC; EC 3.2.1.45; also
known as acid b-glucosidase) (Beutler and Grabowski
2001). This enzyme is responsible for glycosphingolipid
glucocerebroside (glucosylceramide) degradation. Enzyme
deficiency leads to the accumulation of undegraded
substrate, mainly within cells of the monocyte/macrophage
lineage, and this is responsible for the clinical manifes-
tations of the disease. Three types of GD are distinguished
based on neurological involvement. GD is an autosomal
recessive disorder caused by mutations in the glucocere-
brosidase gene or, rarely, by mutations in the GC activator
protein, saposin C (Beutler and Grabowski 2001).
The gene encoding GC (GBA; GenBank accession #
J03059) is located on chromosome 1q21 and spans 7.6 kb
of genomic DNA divided into 11 exons. In addition to the
functional gene, a highly homologous pseudogene sequence
(GBAP; GenBank accession # J03060) is located 16 kb
downstream (Horowitz et al. 1989; Winfield et al. 1997). The
gene and pseudogene are in the same orientation and have
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96 % exonic sequence homology (Horowitz et al. 1989;
Sidransky 2004). To date, more than 350 mutations have been
reported in GBA. These include missense and nonsense
mutations, small insertions or deletions that lead to frameshifts
or in-frame alterations, splice junction mutations, and complex
alleles carrying two or more mutations (Hruska et al. 2008).
The frequencies of specific mutant alleles vary in different
populations. In patients of Ashkenazi Jewish ancestry, four
mutations account for nearly 90 % of the disease alleles.
These mutations are N370S (c.1226A>G), L444P
(c.1448T>C), 84insG (c.84dupG), and IVS2þ1G>A
(c.115þ1G>A). Among non-Jewish patients, these muta-
tions account for about 50–60 % of GD-associated mutations
and there is a broad spectrum of other mutations (Grabowski
and Horowitz 1997; Alfonso et al. 2007).
The diagnosis ofGD is established bymeasuringGC activity
in leukocytes fromperipheral blood and/or fibroblasts from skin
biopsies (Beutler and Grabowski 2001). Molecular analysis
complements this biochemical assay. Our group has been
involved in the biochemical diagnosis of Brazilian patients
with GD for the last 20 years (Michelin et al. 2005). We have
also introduced screening for the common mutations (N370S,
L444P, 84insG, and IVS2þ1G>A). As expected, this
approach is able to detect roughly half the mutant alleles in
our sample population, and just over 60 % of patient
genotypes. Hence, a more comprehensive scheme is desirable
in order to be able to identify the remaining mutant alleles.
We have therefore designed a strategy for analyzing the
entire GBA coding region and applied this approach to 48
unrelated Brazilian patients with GD among 128 patients
referred to our laboratory and previously confirmed by
biochemical analysis. We describe here seven novel mutations
associated with GD, as well as other rare GBA mutations.
Materials and Methods
Patients
In this study, we examined 48 unrelated non-Jewish GD
patients from different regions of Brazil. There were 24
males and 24 females. Ages at diagnosis, when available,
ranged from 2 months to 57 years. The inclusion criteria
were (1) low GC activity in leukocytes and/or fibroblasts
(Michelin et al. 2005) and (2) at least one unidentified
disease-causing allele following screening for the common
mutations (N370S, L444P, 84insG, and IVS2þ1G>A). The
study was approved by our hospital ethics committee.
In order to confirm that we were dealing with meaningful
sequence alterations, we also sequenced GBA in DNA from
104 (208 alleles) healthy Brazilian subjects (52 males and
52 females) to rule out the possibility that some of the novel
variants identified were simply polymorphisms.
Sample Collection and DNA Isolation
Blood samples (5 mL) were collected in EDTA, and genomic
DNA was isolated from peripheral blood leukocytes as
described (Miller et al. 1988) and kept at –20 C. DNA
was quantified with a fluorescence-based kit (Quant-ItTM
dsDNA BR Assay kit; Invitrogen, Carlsbad, CA, USA) in a
QubitTM fluorometer (Invitrogen).
Amplification of the Entire GBA Gene
Long-range polymerase chain reaction (PCR) was used to
selectively amplify the functional GBA gene using primers
GBALF (5 0 CGACTTTACAAACCTCCCTG 3 0)
and GBALR (50 CCAGATCCTATCTGTGCTGG 30); this
generated a fragment of 7765 bp. The long-range PCR
reaction was performed in final volumes of 25 mL
containing 12.5 ng genomic DNA, 200 mM of each dNTP,
0.2 mM of each primer (forward and reverse), 60 mM of
Tris-SO4 (pH 9.1), 18 mM of (NH4)2SO4, 1.7 mM of
MgSO4, and 1 mL of Elongase
® Enzyme Mix (Invitrogen,
Carlsbad, CA, USA). Cycling conditions were initial
denaturation at 94 C for 5 min, followed by 30 cycles of
denaturation at 94 C for 30 s, annealing at 58 C for 30
s and elongation at 68 C for 8 min, with final extension at
68 C for 10 min.
Screening of Common Mutations
Mutations N370S and L444P were screened by genotyping
based on TaqMan® PCR (Applied Biosystems, Foster City,
CA, USA). Primers and probes were designed with Primer
Express® software version 3.0 (Applied Biosystems), and
the primer sequences are shown in Table 1. PCR reactions
were performed in final volume of 12 mL containing 0.5 mL
of the long-range PCR product, 0.3 mL of specific TaqMan
assay medium and 6 mL of 2x PCR Genotyping Master Mix
(Applied Biosystems). Amplification included an initial
step at 50 C for 2 min (activation of the AmpErase UNG
function), AmpliTaq® Gold activation at 95 C for 10 min,
followed by 40 cycles of denaturation at 95 C for 15 s and
annealing extension at 60C for 1 min. The allelic
discrimination step was performed at 60C for 1 min.
PCR products were analyzed by allelic discrimination plot
with Sequence Detection System software version 1.2.1 in
an ABI PRISM® 7500 Sequence Detector System (Applied
Biosystems).
Mutation 84insG was screened by Amplification Refrac-
tory Mutation System-PCR (ARMS-PCR). Two PCR reac-
tions were performed for each sample using different specific
primers to discriminate between wild-type and mutant
alleles. Primers GAU-84GGWRT (50 GCATCATGG-
CTGGCAGCCTCACAGGACTGC 30) and GAU-2R
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(50 GCCCAGGCAACAGAGTAAGACTCTGTTTCA 30)
were used to amplify the wild-type allele, and GAU-
84GGMTF (50 GCATCATGGCTGGCAGCCTCACAG-
GACTGG 30) and GAU-2R for the mutant allele. These
reactions generated a fragment of 255 bp when the allele
sequence was complementary to the primer sequence. Each
PCR reaction was performed in a total volume of 25 mL,
containing 200 ng of genomic DNA, 200 mM of each dNTP,
1 mM of each primer (forward and reverse), 20 mM of Tris
(pH 8.4), 50 mM of KCl, 2.5 mM of MgCl2, and 1.25 U of
Taq DNA polymerase. Amplification conditions were 96 C
for 5 min, followed by 13 cycles of 96 C for 45 s, then 45
s at 70 C 0.5 C/cycle, and 72 C for 45 s, then 22 cycles
of 96 C for 45 s, 64 C for 45 s, and 72 C for 45 s, with
final extension at 72 C for 5 min. Amplified products were
resolved by electrophoresis on 2 % (w/v) agarose gels and
visualized under UV light.
Mutation IVS2þ1G>A was screened by a PCR-
Restriction Fragment Length Polymorphism (PCR-RFLP)
strategy using primers GAU-84GGWRT and GAU-2R
(sequences shown above) that generated a fragment of
255 bp. The PCR reaction was performed in a total volume
of 25 mL, containing 200 ng of genomic DNA, 200 mM of
each dNTP, 1 mM of each primer (forward and reverse),
20 mM of Tris (pH 8.4), 50 mM of KCl, 2.5 mM of MgCl2,
and 1.25 U of Taq DNA polymerase. The amplification
protocol was initial denaturation at 96 C for 5 min, 35
cycles of denaturation at 96 C for 45 s, annealing at 68 C
for 45 s, and extension at 72 C for 45 s, followed by final
extension at 72 C for 10 min. Ten mL of PCR product was
digested in a total volume of 15 mL containing 20 mM of
Tris-acetate, 50 mM of potassium acetate, 10 mM of
magnesium acetate, 1 mM of dithiothreitol (pH 7.9), and
1 U of HphI (New England Biolabs, Ipswich, MA, USA).
The reaction was then placed at 37 C and left overnight,
after which digestion products were resolved by electro-
phoresis on 3 % (w/v) agarose gels and visualized under
UV light. Digestion of the PCR product of the normal allele
generates fragments of 141, 72, and 42 bp, while digestion
of the PCR product of the mutant allele produces fragments
of 213 and 42 bp, because the IVS2þ1G>A mutation
removes an HphI site.
PCR Amplification and Direct DNA Sequencing
Coding sequences and flanking regions (exons 1 to 11) were
amplified by PCR using long-range PCR products as
templates. The GBA coding region was divided into 10
different amplicons, with exons 10 and 11 analyzed together.
PCR reactions were performed in total volumes of 25 mL,
containing 0.5 mL of long-range PCR product, 200 mM of
each dNTP, 0.2 mM of each primer (forward and reverse),
20 mM of Tris (pH 8.4), 50 mM of KCl, 2.5 mM of MgCl2,
and 1.25 U of Taq DNA polymerase. The amplification
protocol was initial denaturation at 94 C for 10 min, 30
cycles of denaturation at 94 C for 30 s, annealing at
57–62 C for 30 s, and extension at 72 C for 30 s, followed
by final extension at 72 C for 10 min. Each PCR product
was verified by electrophoresis on a 1.5 % (w/v) agarose gel
and visualization under UV light. Specific annealing temper-
atures and primer sequences are given in Table 2.
Amplicons were purified using 2.5 U of Exonuclease I
(USB, Cleveland, OH, USA) and 0.25 U of Shrimp
Alkaline Phosphatase (USB, Cleveland, OH, USA). Direct
DNA sequencing was performed with a BigDye® Termina-
tor Cycle Sequencing kit v. 3.1 (Applied Biosystems, Foster
City, CA, USA) following the manufacturer’s instructions,
and sequences were analyzed with DNA Sequencing
Analysis software v. 5.2 (Applied Biosystems) in an ABI
PRISM® 3130xl Genetic Analyzer. All identified mutations
were confirmed by sequencing an independent DNA
sample with forward and reverse primers.
Isolation of Total RNA, cDNA Synthesis, and
PCR Amplification
Total RNAwas isolated fromperipheral blood leukocytes using a
LeukoLOCKTM Total RNA Isolation kit (Applied Biosystems).
Table 1 Sequences of the primers and probes used to identify frequent mutations
Mutation Primer sequence (5´ > 3´) Probe sequence (5´ > 3´)
N370S Forward Normal
GCCTTTGTCTCTTTGCCTTTGTC TTACCCTAGAACCTCCTG – VIC
Reverse Mutant
CCAGCCGACCACATGGTA ACCCTAGAGCCTCCTG – FAM
L444P Forward Normal
CTGAGGGCTCCCAGAGAGT CTGCGTCCAGGTCGT – VIC
Reverse Mutant
GCCATCGGGATGCATCAGT TGCGTCCGGGTCGT – FAM
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RNA was quantified using a fluorescence-based assay (Quant-
ItTM RNA Assay kit) in a QubitTM fluorometer.
RNA samples of 1 mg were used as templates for
complementary DNA (cDNA) synthesis. Reverse transcription
(RT) was performed with a High Capacity cDNA Reverse
Transcription kit (Applied Biosystems) in a total volume of 15
mL. Following the RT reaction, PCR was performed using
primers GAU-G10S (50 CTGAACCCCGAAGGAGGACC
30) and GAU-9/11R (50 GGTTTTTCTACTCTCATGCA 30),
which generated a product of 988 bp. Five microliters of each
RT reaction was used for the PCR in a total volume of 25 mL,
containing 200 mM of each dNTP, 0.8 mM of each primer
(forward and reverse), 20 mM of Tris (pH 8.4), 50 mM of
KCl, 1.5 mM of MgCl2, and 1.25 U of Taq DNA polymerase.
The amplification protocol was initial denaturation at 94 C
for 5 min, 30 cycles of denaturation at 94 C for 30 s,
annealing at 55 C for 30 s, and extension at 72 C for 1 min,
followed by final extension at 72 C for 10 min. An aliquot of
each PCR product was verified by electrophoresis on a 1.0 %
(w/v) agarose gel and visualization under UV light. PCR
products were purified and sequenced as described above.
Evaluation of Novel Mutations
Amino acid sequences of GC from 12 different species were
compared by multiple alignment program in order to
determine whether changes identified in their amino acid
sequences alter conserved residues of GC. The GC sequen-
ces were searched using the protein database from the
National Center for Biotechnology Information (NCBI). The
amino acid sequences were aligned with ClustalW v. 2.0
using the FASTA format.
The novel mutations in the GBA coding region
were analyzed using three web-based tools, PolyPhen
(http://genetics.bwh.harvard.edu/pph) (Ramensky et al.
2002), SNPs3D (http://www.snps3d.org) (Yue and Moult
2006), and SIFT (http://sift.bii.a-star.edu.sg) (Kumar et al.
2009) in order to assess their potential pathogenicity.
Nomenclature of Mutations
The reference sequences used in our study were
NM_000157 and NP_000148. Nucleotide sequences were
numbered from the upstream initiator codon ATG. Amino
acid numbers are those of the mature proteins after cleavage
of the leader sequence. Following the current recommenda-
tion that all variants be described at the most basic level, the
mutations discussed in the text are referred to by the
traditional name of the corresponding allele to facilitate
recognition, followed by the cDNA nomenclature in
brackets (den Dunnen and Antonarakis 2000).
Results
Screening the whole GBA coding sequence in each of the
48 GD patients allowed us to identify 95.8 % of the mutant
alleles, including seven novel sequence variants. These
novel changes were not found among 208 alleles from
normal individuals. Twenty-four rare mutations were also
found among the mutant alleles studied. Data for these 31
variants are summarized in Table 3.
The novel alterations consist of five missense changes
[S125N (c.491G>A), F213L (c.756T>G), P245T
(c.850C>A), W378C (c.1251G>C), and D399H
(c.1312G>C)], one in-frame insertion [982-983insTGC
(c.980_982dupTGC)], and a splicing mutation found in a
complex allele [L461P þ IVS10þ1G>T]. These findings
are described in more detail below.
The first novel sequence alteration is caused by a G to A
change at position 491 of the cDNA (exon 5 of GBA) and
leads to a serine to asparagine substitution at residue 125 of
the protein (S125N). This mutation was found in a male
Table 2 Primers used to amplify and sequence the GBA gene
Exons and flanking regions
Primer sequence (5´ > 3´)
Tannealing(
0C) Length(bp)Forward Reverse
1 CCTAGTGCCTATAGCTAAGG CTGGATTCAAAGAGAGTCTG 57 236
2 GTCCTAATGAATGTGGGAGACC CTTACTGGAAGGCTACCAAAGG 61 286
3 GTTCAGTCTCTCCTAGCAGATG GGAAACTCCATGGTGATCAC 61 353
4 GTCCTCCTAGAGGTAAATGGTG GCAGAGTGAGATTCTGCCTC 61 316
5 GATAAGCAGAGTCCCATACTCTC CTGTACAAGCAGACCTACCCTAC 62 281
6 CTAATGGCTGAACCGGATG GGAAGTGGAACTAGGTTGAGG 62 346
7 CAAAGTGCTGGGATTACAGG CTCTAAGTTTGGGAGCCAGTC 62 404
8 CTAGTTGCATTCTTCCCGTC GCTTCTGTCAGTCTTTGGTG 63 407
9 CTCCCACATGTGACCCTTAC CTCGTGGTGTAGAGTGATGTAAG 61 329
10 and 11 GTGGGTGACTTCTTAGATGAGG CTTTAGTCACAGACAGCGTGTG 62 473
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type 1 GD patient from the south of Brazil who was
diagnosed at 56 years of age and carries the N370S
mutation on the other chromosome. Abdominal pain,
splenomegaly, and chronic bone pain are among the clinical
features of this patient.
Table 3 Alleles defined by this study. The novel sequence variants are shown in bold
GBA mutationsa cDNA nucleotide substitutionb Exon Proteinc # of alleles
Substitutions
R48Q c.260G>A 3 p.Arg87Gln 1
R120Wd c.475C>T 5 p.Arg159Trp 3
M123T c.485T>C 5 p.Met162Thr 1
S125N c.491G>A 5 p.Ser164Asn 1
R131C c.508C>T 5 p.Arg170Cys 1
W179X c.653G>A 6 p.Trp218X 1
N188Sd c.680A>G 6 p.Asn227Ser 1
G202Rd c.721G>A 6 p.Gly241Arg 1
F213L c.756T>G 6 p.Phe252Leu 1
P245T c.850C>A 7 p.Pro284Thr 1
H311R c.1049A>G 8 p.His350Arg 1
Y313H c.1054T>C 8 p.Tyr352His 1
E349K c.1162G>A 8 p.Glu388Lys 1
R353W c.1174C>T 8 p.Arg392Trp 1
N370S c.1226A>G 9 p.Asn409Ser 26
G377S c.1246G>A 9 p.Gly416Ser 12
W378C c.1251G>C 9 p.Trp417Cys 6
N396T c.1304A>T 9 p.Asn435Thr 4
V398I c.1309G>A 9 p.Val437Ile 6
D399H c.1312G>C 9 p.Asp438His 1
L444Pd c.1448T>C 10 p.Leu483Pro 2
I489T c.1583T>C 11 p.Ile528Thr 7
R496H c.1604G>A 11 p.Arg535His 1
Insertions
84insG c.84dupG 2 p.Leu29AlafsX18 1
982-983insTGC c.980_982dupTGC 7 p.Leu327_Pro328insLeu 1
Deletions
413delC c.413delC 4 p.Pro138LeufsX62 1
793delC c.793delC 7 p.Gln265SerfsX5 2
Complex alleles
E326K + L444Pd c.1093G>A 8 p.Glu365Lys 1
c.1448T>C 10 p.Leu483Pro
M361I + N370S c.1200G>A 8 p.Met400Ile 1
c.1226A>G 9 p.Asn409Ser
c.1448T>C 10 p.Leu483Pro
RecNciI c.1483G>C 10 p.Ala495Pro 3
c.1497G>C 10 p.Val499Val
L461Pd + IVS10+1G>T c.1499T>C 10 p.Leu500Pro 1
c.1505+1G>T p.Lys464_Arg502del
aGBA mutations are named according to www.hgvs.org/mutnomen
bNucleotides are numbered from the A of the first ATG
cAmino acid designations (“p.”) are based on the primary GBA translation product, including the 39-residue signal peptide
d These alterations correspond to the normal pseudogene sequence
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The GBA of another type 1 GD patient has a T to G
transversion at base 756 of the cDNA (exon 6 of the gene)
predicting a phenylalanine to leucine substitution at residue
213 of the protein (F213L). The N370S mutation was also
present in this compound heterozygous female type 1 GD
patient. She is from the Southeast of Brazil and was
diagnosed when she was 26 years old. Clinical features
include hepatosplenomegaly and bone pain.
Two novel sequence variants are in exon 7. The first is a
C to A change at position 850 of the cDNA predicting a
proline to threonine substitution at amino acid 245 of
protein (P245T). This was identified in a male type 3 GD
patient from the southeast region of Brazil who is also
heterozygous for RecNciI (c.1448T>C þ c.1483G>C þ
c.1497G>C). This patient is more severely affected, with
neurological involvement. The other alteration in exon 7 is
an in-frame insertion of three nucleotides (TGC) that should
insert an additional leucine residue between positions 327
and 328 of the mature protein (Fig. 1a). This mutation is
referred to as 982-983insTGC and was found in a male type
1 patient from the southeast of Brazil diagnosed at 31 years
of age. The other mutant allele in this patient is N370S, and
his clinical features include hepatosplenomegaly.
Two novel G to C transversions are in exon 9. The first
is at base 1251 of the GBA cDNA and causes a tryptophan
to cysteine substitution at residue 378 of the mature protein
(W378C). This alteration was found in unrelated alleles in
six type 1 GD patients from the north and northeast regions
of Brazil. One of these patients carries the G377S
(c.1246G>A) mutation on the other chromosome, while
the remaining five patients are compound heterozygotes
[N370S] þ [W378C]. All six patients have typical mild
forms of the disease consistent with type 1 disease. The
other G to C transversion is located at position 1312 and is
responsible for an aspartate to histidine substitution at
residue 399 of the protein (D399H). This mutation was
found in a type 1 GD patient diagnosed at 45 years of age
who is also heterozygous for the N370S mutation. The
most characteristic finding in this patient was extreme
hepatosplenomegaly.
Fig. 1 Direct DNA sequencing of the GBA gene. (a) Direct
sequencing of part of exon 7 from the forward primer. The dashed
line shows where three nucleotides (TGC) have been inserted, creating
the 982-983insTGC mutation. (b) Direct sequencing of part of exon
10 from the forward primer. The first arrow indicates the T to C
substitution (c.1499T>C) in the L461P mutation, while the second
arrow points to the G to T substitution in the IVS10+1G>T variant.
(c) Direct sequencing of part of exon 10 from the reverse primer. The
first arrow indicates the C to A substitution in IVS10+1G>T, while
the second arrow points to the A to G substitution in L461P
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The remaining novel mutation involves a G to T trans-
version in the splice donor site at the first nucleotide of intron
10 (Fig. 1b and c). This mutation, named IVS10þ1G>T,
removes the conserved splice donor sequence and results in
skipping of exon 10. RT-PCR amplification of the GBA
cDNA from this patient revealed an 871 bp fragment in
addition to the expected 988 bp fragment (from the other
allele) (data not shown). This smaller product was sequenced
and shown to lack exon 10, presumably due to loss of the
splice donor site at the end of exon 10 (Fig. 2b). A control
cDNA used at the same time yielded a normal splicing
pattern and a fragment of the expected length (Fig. 2a).
Schematic representations of the normal and aberrant
splicing patterns are shown in Fig. 2c and d, respectively.
This variant was found in a female type 1 patient from the
south of Brazil diagnosed at 3 years of age. N370S and
L461P (c.1499T>C) were also present in this patient. As
DNA from her parents was also available, we were able to
show that the N370S mutation was of paternal origin, while
L461P and IVS10þ1G>T were of maternal origin.
In silico evaluation of the five novel sequence variants
using PolyPhen, SNPs3D, and SIFT predicted defective
proteins for S125N, W378C, and D399H. However, the
three bioinformatics tools differed in their predictions for
the F213L and P245T variants. PolyPhen predicted that
they would be deleterious whereas according to SNPs3D
and SIFT, they were non-deleterious.
We also estimated the frequencies of the common
previously reported mutations taking into account all 128
patients referred to our laboratory. As expected, the most
frequent mutation was N370S, found in 113 alleles (44.1 %);
the second most frequent mutation in our cohort, L444P, was
found in 73 alleles (28.5 %); and G377S, the third most
frequent mutation, accounted for 12 mutant alleles (11.1 %).
This was followed by I489T (c.1583T>C) seven alleles
(6.5 %), W378C and V398I (c.1309G>A) six alleles each
(5.6 %), RecNciI three alleles (2.8 %), IVS2þ1G>A two
alleles (1.9 %), and [E326K þ L444P] one allele (0.9 %).
The genotypes of the 48 GD patients examined in this
study are shown in Table 4. Genotypes involving only
combinations of the common mutations were excluded.
Discussion
The protocol described here allowed us to identify seven
novel sequence variants of the GBA gene in patients with
GD. These include five missense mutations (S125N,
F213L, P245T, W378C, and D399H). We also found that
the G377S mutation was common among the patients in
this study, as previously reported by other Brazilian groups
(Rozenberg et al. 2006; Sobreira et al. 2007). Therefore,
G377S should be included in preliminary screening of
Brazilian GD patients.
Fig. 2 Direct sequencing of GBA cDNA. (a) Wild-type alleles
sequenced from the forward primer. The dashed line indicates the
boundary between exons 9 and 10. (b) Normal and mutant alleles
from a GD patient carrying IVS10+1G>T, sequenced from the
forward primer. The dashed lines indicate the boundary between
exons 9 and 10 in the normal allele and between exons 9 and 11 in the
mutant allele, respectively. Schematic diagrams of (c) the normal
splicing pattern and (d) the aberrant splicing pattern due to the
IVS10+1G>T mutation
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The S125N mutation involves the replacement of a polar
uncharged amino acid with a hydroxyl group by an
uncharged residue with an amide group containing a long
side chain. Ser125 is conserved in several species from
human to worms, arguing in favor of a role in enzyme
function (Fig. 3). This mutation destroys a PvuII restriction
site. The S125N mutation was previously reported in
patients with Parkinson disease (Lesage et al. 2011);
however, this sequence alteration has not been identified
in GD patients to date.
The F213L mutation replaces a bulky aromatic amino
acid by a residue containing an open aliphatic chain, which
possibly changes the protein conformation. Although in
silico evaluation predicts a non-deleterious effect on
GC, this phenylalanine residue is conserved in several
species, such as chimpanzee, orangutan, rat, mouse, dog,
pig, ox, and horse (Fig. 3).
The other mutation, P245T, involves the replacement of a
cyclic aliphatic structure by an open polar uncharged chain
and would be expected to affect protein structure and/or
activity. In silico evaluation of P245T predicted a non-
deleterious effect on the mature protein. However, the
proline residue is conserved in mammals such as chimpan-
zee, orangutan, rat, mouse, dog, pig, ox, and horse (Fig. 3).
The mutation in exon 9, W378C, involves the replace-
ment of an amino acid with an indole side chain by an
amino acid with a sulfhydryl group, which may affect
protein conformation. In silico analysis predicted a delete-
rious effect. The tryptophan residue is highly conserved,
indicating a considerable degree of structural and functional
relevance (Fig. 3). This mutation creates an HpyCH4V
restriction site within GBA.
D399H involves the replacement of an acidic amino acid
by a basic one, which is again likely to affect protein
structure and/or function. Asp399 is highly conserved, and in
silico analysis predicts a deleterious effect of the mutation
(Fig. 3). This mutation destroys a HindII restriction site.
Two other variants likely to have harmful effects are an
insertion and a single base change at the first position of a
splice donor site. Despite being an in-frame insertion, the
insertion of an additional residue in the mature protein is
likely to disturb normal folding and function. The point
mutation in the first base of the splice donor site disrupts
normal splicing, giving rise to exon 10 skipping, which
yields a truncated protein of 458 amino acids
(p.Lys464_Arg502del).
Most of the novel sequence alterations detected in this
study were found in patients with the N370S mutation at
the other locus. It appears that this allele when part of any
genotype is able to protect patients from neurological
involvement (Alfonso et al. 2001). Indeed, no neurological
involvement was reported in any of our patients of this
type. Moreover, neurological impairment is not seen in GD
patients who carry N370S or 982-983insTGC, which
further support a protective effect of the N370S mutation.
Interestingly, the G377S mutation was also found to be
the third most frequent among GD patients in Portugal and
Spain (Amaral et al. 1996). This alteration appears to be
neuroprotective since homoallelic patients are essentially
asymptomatic or have mild disease (type 1) (Amaral et al.
2000). However, other workers have detected type 3 patients
with one copy of G377S (Beutler et al. 2005; Rozenberg
et al. 2006). Thus we cannot rule out an allele-dose effect in
which two copies of G377S generate sufficient residual
enzymatic activity to prevent neurological involvement,
whereas one copy combined with a severe second allele
Table 4 Frequencies of the identified genotypes
Genotype # of patients
[N370S] + [W378C] 5
[G377S] + [G377S] 4
[V398I] + [V398I] 3
[N370S] + [I489T] 3
[R120W] + [N370S] 3
[793delC] + [N370S] 2
[N370S] + [L461P + IVS10+1G>T] 1
[Y313H] + [L444P] 1
[G377S] + [I489T] 1
[R353W] + [RecNciI] 1
[F213L] + [N370S] 1
[W179X] + [M361I + N370S] 1
[N188S] + [RecNciI] 1
[M123T] + [E349K] 1
[G377S] + [W378C] 1
[S125N] + [N370S] 1
[P245T] + [RecNciI] 1
[N396T] + [N396T] 1
[N370S] + [D399H] 1
[413delC] + [N370S] 1
[I489T] + [I489T] 1
[N370S] + [G377S] 1
[N396T] + [I489T] 1
[N396T] + [L444P] 1
[G202R] + [N370S] 1
[R131C] + [N370S] 1
[84insG] + [R496H] 1
[H311R] + [N370S] 1
[982-983insTGC] + [N370S] 1
[G377S] + [E326K + L444P] 1
[N370S] + [?] 3
[R48Q] + [?] 1
Total 48
? denotes unidentified mutation
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Fig. 3 Alignment of the GC amino acid sequences of several
organisms. (a) Human (Gene ID 2629); (b) chimpanzee (Gene ID
449571); (c) orangutan (Gene ID 100174563); (d) rat (Gene ID
684536); (e) mouse (Gene ID 14466); (f) dog (Gene ID 612206);
(g) pig (Gene ID 449572); (h) ox (Gene ID 537087); (i) horse (Gene
ID 100063514); (j) tick (Gene ID 8051161); (k) C. elegans (Gene ID
178535); (l) honeybee (Gene ID 409708). The boxes indicate
conserved residues altered in novel missense mutations. The designa-
tion of each mutation is given above the appropriate box
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leads to type 3 GD (Rozenberg et al. 2006). Such a model
predicts that our patient with [G377S] þ [E326K þ L444P]
is likely to develop neurological symptoms, although no
such symptoms have been described to date.
There remain undefined mutant alleles in our collection
that can be explained by alterations outside the GBA coding
region. Such changes would not be detected by our approach,
nor would sequence alterations in the promoter region of the
gene, or in untranslated or in noncoding regions. We are
currently testing further approaches to overcome these
limitations and unmask the remaining mutant alleles.
The vast majority of mutations identified have not been
found in homoallelic form, especially the new variants.
Ultimately, it may be more accurate to envision the
associated phenotypes as forming a continuum, with the
major distinction being the presence and degree of neurolog-
ical involvement (Sidransky 2004; Hruska et al. 2008).
The identification of mutant alleles is crucial for
advancing knowledge of the worldwide GBA mutation
spectrum, and should contribute to a better understanding
of the molecular basis of the disease. Such information
should also help in establishing genotype-phenotype corre-
lations as well as in genetic counseling and/or in custom-
ized molecular analyses for families at risk.
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